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Abstract
Preliminary data suggest that allogeneic stem cell transplantation (allo-SCT) may be effective in T-prolymphocytic leukemia
(T-PLL). The purpose of the present observational study was to assess the outcome of allo-SCT in patients aged 65 years or
younger with a centrally confirmed diagnosis of T-PLL. Patients were consecutively registered with the EBMT at the time of
transplantation and followed by routine EBMT monitoring but with an extended dataset. Between 2007 and 2012, 37
evaluable patients (median age 56 years) were accrued. Pre-treatment contained alemtuzumab in 95% of patients. Sixty-two
percent were in complete remission (CR) at the time of allo-SCT. Conditioning contained total body irradiation with 6 Gy or
more (TBI6) in 30% of patients. With a median follow-up of 50 months, the 4-year non-relapse mortality, relapse incidence,
progression-free (PFS) and overall survival were 32, 38, 30 and 42%, respectively. By univariate analysis, TBI6 in the
conditioning was the only significant predictor for a low relapse risk, and an interval between diagnosis and allo-SCT of
more than 12 months was associated with a lower NRM. This study confirms for the first time prospectively that allo-SCT
can provide long-term disease control in a sizable albeit limited proportion of patients with T-PLL.
Introduction
T-prolymphocytic leukemia (T-PLL) is a rare neoplasm
belonging to the mature T-cell lymphomas according to the
WHO classification. The disease has usually an aggressive
course with a median survival of less than one year with
standard chemotherapy. A major therapeutic improvement
was achieved following the introduction of alemtuzumab,
which results in overall response rates in >90% of patients,
including a high proportion of complete responses (CR)
when given intravenously first-line as single agent or as part
of a chemoimmunotherapy program [1–3]. These responses
were, however, associated with limited duration and the
prognosis remained rapidly fatal, prompting investigators to
explore allogeneic stem cell transplantation (allo-SCT) in T-
PLL.
Initial analyses of the use of allo-SCT in T-PLL sug-
gested that a long-term disease control might indeed be
possible in a proportion of patients as indicated by 3-year
progression-free survival (PFS) rates between 20 and 30%
[4–7]. However, all these studies are retrospective, included
mostly transplants performed before 2005 and were limited
by considerable heterogeneity in terms of patient baseline
characteristics and transplant strategies.
The purpose of the present observational study was to
prospectively follow patients with a centrally confirmed
diagnosis of T-PLL who underwent an allo-SCT from an
HLA-identical donor in a non-progressive disease status and
were registered with the EBMT at the time of transplant.
Given the notion that without transplantation, all patients
with T-PLL responding to first-line therapy will inevitably
relapse, usually after a short remission duration, and are
difficult to salvage [8], first-line transplants have been
increasingly used in recent years.
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Patients and Methods
Data source
EBMT is a voluntary organization comprising more than
500 transplant centers mainly from Europe. Accreditation as
a member center requires submission of minimal essential
data (MED-A form) from all consecutive patients to a
central registry in which patients may be identified by the
diagnosis of the underlying disease and type of transplan-
tation. All transplant centers have to obtain written informed
consent prior to data registration with the EBMT following
the Helsinki Declaration 1975. Individual IRB approvals
were obtained at the participating center level where
appropriate.
Study design
Eligible for this registry-based prospective observational
study were all the consecutive patients aged 18–65 years
who underwent a planned allo-SCT from an HLA-identical
related or unrelated donor for non-progressive T-PLL at the
participating 25 EBMT centers. Baseline patients’ and dis-
ease characteristics were submitted along with the regis-
tration for the study at the time of admission for allo-SCT.
Details on pre-transplantation treatment and transplantation
were collected subsequently according to EBMT proce-
dures. In addition, submission of a written diagnostic his-
topathology and/or immunophenotyping report
confirmatory for a diagnosis of T-PLL was mandatory for
inclusion in the study. The full protocol of the study
including the diagnostic criteria applied can be found in
the supplemental Appendix (online only). Accrual target
was 50 patients.
Statistical analysis
The primary endpoint was non-relapse mortality (NRM),
defined as death in the absence of relapse or progression
since allo-SCT. Secondary endpoints were overall survival
(OS), PFS and incidence of disease relapse or progression
(RI). Additional endpoints were grade II–IV and III–IV
acute graft-versus-host disease (GVHD), and limited and
extensive chronic GVHD. OS was defined as the time from
allo-SCT to death from any cause and PFS was defined as
the time from allo-SCT to relapse or progressive disease or
death from any cause, whichever came first. The prob-
abilities for OS and PFS were estimated from the time of
allo-SCT using the Kaplan–Meier product-limit estimator
and differences in subgroups were assessed by the log-rank
test. The median follow-up was calculated using the reverse
Kaplan–Meier estimator. Estimates of NRM and RI were
calculated using cumulative incidence rates to
accommodate competing risks and were compared by
Gray’s test. Each of the primary and secondary endpoints
were evaluated at 48 months. Acute and chronic GVHD
were estimated as the cumulative incidence of grade II–IV
and III–IV acute GVHD, and limited and extensive chronic
GVHD respectively, with death from any cause as the
competing event. Acute GVHD was evaluated at 100 days,
and both forms of chronic GVHD were evaluated at
12 months. The impact of chronic GVHD on outcome was
analyzed by means of a Cox model in which the occurrence
of chronic GVHD was included as a time-dependent cov-
ariate. Because of the small number of events, only uni-
variate analyses were performed. P-values <0.05 were
considered significant. All estimates are reported with
accompanying 95% confidence intervals in brackets. All
analyses were performed in R version 3.2.2. using packages
‘survival’, ‘prodlim’ and ‘cmprsk’.
Results
Study population
Between January 2007 and May 2012, 54 patients from 25
European centers were registered for this study. Of these, 4
patients were excluded because the written diagnostic
reports were considered as not confirmative for a diagnosis
of T-PLL after central review (T-lymphoblastic leukemia/
lymphoma – 2, aggressive NK-cell leukemia – 2). Another
11 patients did not meet baseline eligibility because they
were older than 65 years [4], had progressive disease at allo-
SCT [2], or were allografted with cord blood [3] or a mis-
matched unrelated donor [2]. For 2 additional patients,
follow-up data beyond registration information was not
provided, leaving 37 patients evaluable for study endpoints.
Patients’ characteristics
Patients’ characteristics and transplant strategies are sum-
marized in Table 1. There was a male predominance and the
median age was 56 years at transplant. The majority of
patients had received the allo-SCT in first CR or partial
remission (PR); 65% of the patients underwent the trans-
plant within the first year after diagnosis and 92% within 2
years. Only the 2 patients who had undergone an auto-
logous SCT as part of the first-line strategy had a sub-
stantially longer time interval from diagnosis to
allotransplant of 42 and 48 months, respectively. Almost all
patients had been exposed to alemtuzumab prior to trans-
plantation with a median time interval between the last
alemtuzumab dose and the allo-SCT of 75 days (inter-
quartile range 53–152). Alemtuzumab was administered
either as monotherapy or in combination with different
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chemotherapy regimens, mostly fludarabine-based or
CHOP. Conditioning intensity was considered as myeloa-
blative by the Working group criteria [9] in 35% of the
patients. Total body irradiation (TBI) of doses of 6 Gy or
higher were administered to 30% of patients.
Outcome
Except for a single patient with early death, all patients
engrafted. Acute GvHD grade II–IV before day 100 was
reported in 19% (6–32%) of patients and acute GvHD grade
III–IV in 11% (1–21%). The cumulative incidence of
overall and extensive chronic GVHD at 12 months post
allo-SCT was 43% (27–59%) and 21% (7–35%),
respectively.
Twelve patients died of NRM at a median time of 6 (0.5–
74) months after allo-SCT, corresponding to NRM inci-
dences of 25% (11–39%) and 32% (16–47%) at 2 and 4
years, respectively. T-PLL recurrence was reported in 13
patients, with only 2 relapses occurring beyond 24 months
post-transplantation, translating into a 4-year RI of 38%
(22–55%). With a median follow-up of surviving patients of
50 months (range 12–78), the 4-year OS and PFS were 42%
(25–59%) and 30% (14–46%), while the median OS and
PFS was 27.8 and 19.2 (11.6–46.7) months, respectively
(Fig. 1).
Prognostic factors
By univariate analysis taking into account age, gender, time
from diagnosis to first treatment, time from first treatment to
transplantation, time from diagnosis to transplantation,
interval between alemtuzumab withdrawal and allo-SCT,
type of previous treatment (alemtuzumab monotherapy
versus chemoimmunotherapy versus chemotherapy only),
disease status at transplantation, type of donor, TBI >6Gy in
the conditioning and conditioning intensity, significant
predictors of a favorable outcome were an interval from
diagnosis to allo-SCT >12 months (for NRM) and use of a
conditioning regimen containing TBI dosed with 6Gy or
more (for RI) (Table 2). The 4-year PFS of patients in CR at
transplant was 41 (19–61) vs 15% (0–35), which did not
reach statistical significance. There was no impact of
chronic GVHD, analyzed as a time-dependent covariate, on
both relapse incidence and survival, the HRs being 0.81
(0.25–2.64), p= 0.73 and 0.94 (0.33–2.7), p= 0.908.
Discussion
This observational study aimed at prospectively investi-
gating the outcome of allo-SCT in consecutive T-PLL
patients fulfilling well-defined baseline characteristics (age
Table 1 Patients’ characteristics and transplant strategies in T-PLL,
separately for all patients and patients who received at least 6Gy TBI
or less than 6Gy TBI
Variable All patients TBI < 6Gy TBI >=6Gy
Number of patients 37 26 11
Age at transplantation
(years; median, IQR)
56 (47–59) 56 (49–59) 56 (44–59)
Gender male 27 (73%) 20 (77%) 7 (64%)
Interval from diagnosis
to 1st treatment line
<= 3 months
25 (69%)a 16 (64%) 9 (82%)
Interval from 1st
treatment line to allo-
SCT <= 12 months
31 (86%)a 21 (84%) 10 (91%)
Interval from diagnosis to
allo-SCT <= 12 months
24 (65%) 15 (58%) 9 (82%)
Months from diagnosis to
allo-SCT (median, IQR)
8 (6–17) 11 (6–18) 6 (5–7)
Number of treatment lines prior to allo-SCT
1 26 (72%) 18 (72%) 8 (73%)
2 8 (22%) 5 (20%) 3 (27%)
>2 2 (6%)a 2 (8%) 0 (0%)
First-line alemtuzumab ->
intent-to-first- line allo-
SCT strategy pursued,
thereof
28 (80%) 19 (73%) 9 (82%)
Alemtuzumab
monotherapy
18 (51%) 14 (54%) 4 (36%)
Chemoimmunotherapy 10 (29%)b 5 (19%) 5 (45%)
Previous alemtuzumab
(in any line)
35 (95%) 24 (92%) 11 (100%)
Days between the last
alemtuzumab dose and
allo-SCT (median, IQR)c
75 (53–152) 85 (61–152) 61 (50–70)
Performance status at transplantation (Karnofsky)
90–100 24 (69%) 16 (67%) 8 (73%)
70–80 11 (31%)b 8 (33%) 3 (27%)
Disease status at transplantation
CR 1 16 (44%) 12 (67%) 4 (36%)
CR>1 6 (17%) 3 (12%) 3 (27%)
PR 1 8 (22%) 5 (20%) 3 (27%)
PR>1 1 (3%) 1 (4%) 0 (0%)
PR or CR>1 1 (3%) 1 (4%) 0 (0%)
SD 4 (11%)a 3 (12%) 1 (9%)
Conditioning
Myeloablative 13 (35%) 6 (23%) 7 (64%)
Reduced-intensity 24 (65%) 20 (77%) 4 (36%)
Conditioning (TBI-based)
Myeloablative 7 (19%) 0 (0%) 7 (64%)
Reduced-intensity 6 (16%) 2 (100%) 4 (36%)
TBI
2Gy 2 (5%) 2 (100%) 0 (0%)
6Gy 4 (11%) 4 (36%)
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<65, good performance status, sensitive disease, well-
matched donor) in registered EBMT centers, thereby
avoiding the selection bias and heterogeneity inherent to the
few retrospective case series [4–7], which represent the only
source of information on allo-SCT in T-PLL available to
date. Focusing on patients with a favorable disease and
transplant risk, the outcome in this study with 4-year OS
and PFS estimates of 42 and 30%, respectively, tends to be
superior to what has been observed in the retrospective
registry studies mentioned, though the improvement does
not seem to be substantial.
Almost all of our patients had been pre-treated with
alemtuzumab prior to transplant, most of them following an
intent-to-transplant-in-CR1 strategy. This resulted only in a
modest outcome improvement in the patients actually
transplanted as captured by this study, if any. Nevertheless,
it might well have been that this approach has resulted in a
higher proportion of patients achieving CR (and thus opti-
mum transplant eligibility) than with chemotherapy alone.
Notably, we did not observe an adverse effect of the time
interval between alemtuzumab withdrawal and allo-SCT on
post-transplant disease control, suggesting that outcome
was not heavily affected by in-vivo T-cell depletion caused
by alemtuzumab serum levels persisting beyond the date of
transplant. There was also no relation between the time
interval between alemtuzumab withdrawal and allo-SCT in
terms of non-relapse mortality and acute GVHD occurrence.
However, both NRM and long-term disease control
provided by allo-SCT even if performed in profound CR are
still unsatisfactory. Therefore, the development of novel
additional therapeutic tools for targeting residual T-PLL
causing post-transplant relapse is eagerly awaited. (Alem-
tuzumab is unsuitable for this purpose since it strongly
counteracts any graft-versus-leukemia (GVL) activity and
has no durable effect per se in T-PLL [8].) Whether new
agents such as venetoclax [10], anti-HDAC inhibitors e.g.
romidepsin (NCT02512497), JAK/STAT pathway inhibi-
tors [11] or PARP inhibitors [12] will be helpful in main-
tenance or preemptive treatment after allo-SCT is a matter
of future studies. As long as such agents are unavailable,
bridging the time gap until GVL becomes effective relies
essentially on the conditioning regimen. To this end, we did
not find a significant impact of conditioning intensity on
post-transplant disease control, but notably those patients
who had received TBI dosed 6 Gy or higher had a sig-
nificantly lower relapse risk by univariate analysis than
Table 1 (continued)
Variable All patients TBI < 6Gy TBI >=6Gy
8Gy 1 (3%) 1 (9%)
12Gy 4 (11%) 4 (36%)
13Gy 1 (3%) 1 (9%)
14.4Gy 1 (3%) 1 (9%)
T-cell depletion
No 17 (46%) 11 (42%) 6 (55%)
In vivo 19 (51%) 14 (54%) 5 (46%)
ATG 13 (35%) 9 (35%) 4 (36%)
Alemtuzumab 6 (16%) 5 (19%) 1 (10%)
Ex vivo 1 (3%) 1 (4%) 0 (0%)
Donor type
Matched related 15 (43%) 11 (42%) 4 (36%)
Matched unrelated 22 (57%) 15 (58%) 7 (64%)
Source of stem cells
Peripheral blood 36 (97%) 26 (100%) 10 (91%)
Bone marrow 1 (3%) 0 (0%) 1 (9%)
GvHD prophylaxis
Cyclosporine and
methotrexate
17 (46%) 10 (38%) 7 (64%)
Cyclosporine and MMF 8 (22%) 8 (31%) 0 (0%)
Methotrexate alone 2 (5%) 1 (4%) 1 (9%)
MMF alone 2 (5%) 2 (8%) 0 (0%)
Cyclosporine alone 6 (16%) 5 (19%) 1 (9%)
Other 2 (5%) 0 (0%) 2 (18%)
aData available for 36 patients
bData available for 35 patients
cData available for 27 patients
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0C
um
u
la
tiv
e
 in
ci
de
nc
e
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pr
ob
ab
ilit
y
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Pr
ob
ab
ilit
y
0
37 28 24 16 14 13 13 10 8N at risk:
6 12 18 24 30 36 42
Months since Tx
Months since Tx
Months since Tx
48
0
37 28 24 16 14 13 13 10 8N at risk:
6 12 18 24 30 36 42 48
0
37 30 25 21 17 16 16 14 12N at risk:
6 12 18 24 30 36 42 48
a
b
c
Fig. 1 Non-relapse mortality (a), progression-free survival (b), and
overall survival (c) of all 37 patients
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those patients whose conditioning regimen was based on
low-dose TBI or chemotherapy only. The importance of
TBI is in keeping with preliminary findings from our pre-
vious study [6] and suggests that TBI ≥ 6 Gy may be the
preferred conditioning backbone for patients with T-PLL
as long as no contrary evidence becomes available.
Intermediate-dose TBI conditioning can be safely applied
also in elderly patients who represent the bulk of the T-PLL
target population [13]. However, since the event number
was too low for a robust multivariate analysis and the
sample size still small, a definite conclusion of the super-
iority of intermediate-dose TBI over alternative condition-
ing regimens cannot be drawn. Even if further studies on
this issue are needed, it still seems to be reasonable to prefer
intermediate-dose TBI, where it is available. In contrast to
our previous study, a short interval between diagnosis and
allo-SCT was not associated with a favorable outcome, but
with an increased NRM risk. One explanation for this dis-
crepancy might be the fact that unlike in the current
study, in the previous EBMT series containing transplants
largely performed in the pre-alemtuzumab era, many
chemotherapy-refractory patients may have undergone
lengthy remission induction attempts before proceeding to
allo-SCT [6]. No other prognostic factors for post allo-SCT
outcome have been identified so far [4, 5, 7].
Apart from TBI, the only other susceptible variable
affecting outcome – though not reaching statistical sig-
nificance – was being in CR at the time of transplant, again
highlighting the need for novel therapeutic tools effectively
targeting T-PLL. In contrast, the number of pre-treatment
regimens did not affect outcome as long as a CR was pre-
sent at the time of allo-SCT. However, since a second CR
might be very difficult to achieve in T-PLL once disease has
recurred after a first CR [8], the obvious conclusion from
this finding is that eligible patients should proceed to
transplant as soon as the first remission is reached if an allo-
SCT is considered at all.
As in most other indications, the efficacy of allo-SCT
in T-PLL basically relies on the existence of GVL activity
in this disease. Although a clear plateau did not emerge,
only 2 relapses occurred beyond two years post-trans-
plant, pointing to a protracted GVL effect in the long-term
survivors similar to the observations made in the retro-
spective series. However, it has to be kept in mind that
long-term PFS has been observed also in anecdotal T-PLL
cases after autoHCT [4]. Anyway GVL efficacy seems to
be less effective in T-PLL than in other lymphoid
malignancies, such as chronic lymphocytic leukemia
(CLL) [14]. This hypothesis is based on the generally
poorer long-term outcome of allo-SCT for T-PLL com-
pared to CLL, and also on recent data on minimal residual
disease kinetics related to immune-modulating events in
T-PLL [15].
In keeping with this, the results of the present study were
disappointing, taking into account that it was focusing on
early transplantation in patients with sensitive disease. This
raises the question if early allo-SCT consolidation is the
way to go in T-PLL. A recent case series from the MD
Anderson Cancer Center did not find an outcome advantage
for 16 patients undergoing allo-SCT in CR1 compared to 26
patients without CR1 transplant consolidation [16]. The
reason was that unlike in the current and the other larger
published studies [4–7], long-term remissions after allo-
SCT were not observed in the MD Anderson series. This
might be due to the fact that the study covered a long period
of 27 years, whereas our analysis is restricted to the most
recent period of time.
The limitations of this study consist in the relatively
small sample size and in the heterogeneity of the transplant
strategies pursued. In addition, although participating cen-
tres pledged themselves to enroll all eligible patients it
cannot be excluded that patients erroneously got lost
because site monitoring was not performed. Nevertheless, it
is the first study prospectively following consecutive
patients meeting defined eligibility criteria from the time of
allo-SCT. Moreover, it is the first T-PLL transplant study
employing central review of diagnostic reports for validat-
ing the diagnosis of T-PLL.
In conclusion, this study confirms for the first time pro-
spectively that allo-SCT is the only modality, which can
provide long-term disease control in a sizable fraction of
patients with T-PLL. In transplant-eligible patients, allo-
SCT should be pursued as soon as a CR is achieved, and
using intermediate/high-dose TBI seems to be recom-
mendable. Novel therapeutic tools are needed to improve
the outcome of allo-SCT and the prognosis of T-PLL
patients in general; first suggestions regarding targeted
therapy are coming from high-throughput studies [17].
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